A vaccine made by the Moderna pharmaceutical company against the novel corona virus is showing promising signs. The firm had partnered with the US National Institute of Health to find a cure. If early results of the phase one trial is an indication, the vaccine may actually be available for public consumption by January of next year.
Dr. Tal Zaks, chief medical officer of Moderna told CNN that early data coming from the phase I clinical trial shows very bright results. Moderna vaccinated dozens of COVID-19 patients and measured antibodies in eight of them. All eight reportedly developed antibodies to the virus at levels reaching or exceeding levels seen in people who naturally recovered from the dreaded disease.
Results of the study, co-authored by the National Institutes of Health, have not been peer-reviewed or published in a medical journal though. Dr. Paul Offit, a member of the NIH panel says that the development of antibodies is a great sign because it shows that the antibody prevented the virus from infecting other cells.
The FDA had cleared Moderna for the phase II trials which will involve more people. Large scale clinical trials, known as Phase-3, begins in July.
